TopFunds

Biogen

NASDAQ: BIIB

Stock price

218.43 USD

(+0%) TODAY

BiotechnologyDrug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
15.3
16.9
11.9
21.6
31.4
24.8
10.4
20.9
8
11.2
8.8
(5.4)%
02Free cash flow per share
13.3
17.9
17.3
26.4
35
23.6
22.6
7.8
8.5
17.2
14
0.5%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
10,764
11,449
12,274
13,453
14,378
13,445
10,982
10,173
9,836
9,676
9,811
(0.9)%
06% Change
-
-
-
-
-
-
-
-
-
-
-
(0.9)%
07Cost of revenue
(1,240)
(1,433)
(1,630)
(1,816)
(1,955)
(1,805)
(2,110)
(2,278)
(2,533)
(2,310)
(2,897)
8.9%
08Gross profit
9,523
10,016
10,644
11,637
12,423
11,639
8,872
7,895
7,302
7,366
6,914
(3.2)%
09% Margin
88.5%
87.5%
86.7%
86.5%
86.4%
86.6%
80.8%
77.6%
74.2%
76.1%
70.5%
81.9% A
10Operating expenses
(4,632)
(4,864)
(5,298)
(5,748)
(5,380)
(7,046)
(6,081)
(5,006)
(5,205)
(4,875)
(5,036)
0.8%
11% of Revenue
(43)%
(42.5)%
(43.2)%
(42.7)%
(37.4)%
(52.4)%
(55.4)%
(49.2)%
(52.9)%
(50.4)%
(51.3)%
(47.3)% A
12Operating Income
4,891
5,152
5,346
5,889
7,043
4,593
2,791
2,889
2,097
2,490
1,878
(9.1)%
13Income tax expense
(1,162)
(1,237)
(2,459)
(1,426)
(1,158)
(992.3)
(52.5)
(632.8)
(135.3)
(273.8)
(108.1)
(21.1)%
14Net Income
3,547
3,703
2,539
4,431
5,889
4,001
1,556
3,047
1,161
1,632
1,293
(9.6)%
15% Margin
33%
32.3%
20.7%
32.9%
41%
29.8%
14.2%
30%
11.8%
16.9%
13.2%
25.1% A
16Shares Outstanding
231.2
218.8
213
205.3
187.4
161.3
149.6
146
145.6
145.9
146.7
(4.5)%
17EPS Basic
15.4
17
11.9
21.6
31.5
24.9
10.4
21
8
11.2
8.9
(5.4)%
18EPS Diluted
15.3
16.9
11.9
21.6
31.4
24.8
10.4
20.9
8
11.2
8.8
(5.4)%
19EBITDA
5,615
6,346
6,608
7,015
7,740
5,108
3,923
3,537
2,377
2,996
3,101
(5.8)%
% Margin
52.2%
55.4%
53.8%
52.1%
53.8%
38%
35.7%
34.8%
24.2%
31%
31.6%
42.1% A
20Net Interest Income (expense)
(73.4)
(196.6)
(172.3)
(88.1)
(67.4)
(180.5)
(242.6)
(157.3)
29.6
(182.7)
(158.2)
8%
21Net Debt / EBITDA
0.9
0.7
0.7
0.7
0.4
1.3
1.4
0.9
2.6
1.4
1.3
1.1 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
1,308
2,327
1,574
1,225
2,914
1,331
2,261
3,419
1,050
2,375
3,009
8.7%
23Short-term investments
2,121
2,569
2,115
2,313
1,562
1,279
1,541
1,474
-
-
807.2
(9.2)%
24Accounts receivable
1,542
1,742
2,320
2,485
2,471
2,327
1,962
2,136
2,100
1,869
1,867
1.9%
25Other current assets
836.9
1,093
962
958.8
631
881.1
740.8
1,418
1,182
752.5
1,123
3%
26Inventory
893.4
1,002
902.7
929.9
804.2
1,069
1,352
1,344
2,527
2,461
2,168
9.3%
27Total Current Assets
6,700
8,732
7,873
7,641
8,382
6,887
7,857
9,791
6,859
7,457
8,974
3%
Non-Current Assets
28Net property, plant & equipment
2,188
2,502
3,182
3,601
3,674
3,845
3,792
3,703
3,730
3,538
3,321
4.3%
29Long-term investments
2,760
2,829
3,057
1,376
1,408
772.1
892
705.7
460.7
226.7
750.6
(12.2)%
30Other non-current assets
7,857
8,813
9,540
12,671
13,770
13,115
11,337
10,355
15,795
16,828
16,394
7.6%
31Total Non-Current Assets
12,805
14,145
15,779
17,648
18,853
17,732
16,021
14,763
19,986
20,593
20,465
4.8%
Total Assets
19,505
22,877
23,653
25,289
27,234
24,619
23,877
24,554
26,845
28,049
29,440
4.2%
LIABILITIES
Current Liabilities
32Accounts payable
267.4
279.8
395.5
370.5
530.8
454.9
589.2
491.5
403.3
424.2
432
4.9%
33Short-term debt
4.8
4.7
3.2
-
1,496
-
999.1
-
150
1,749
80.4
32.6%
34Other current liabilities
2,306
3,135
2,970
2,925
2,837
3,287
2,710
2,781
2,881
3,356
2,837
2.1%
35Total Current Liabilities
2,578
3,420
3,368
3,295
4,864
3,742
4,298
3,273
3,434
5,529
3,349
2.7%
Non-Current Liabilities
36Long-term debt
6,522
6,513
5,935
5,937
4,872
7,828
6,604
6,614
7,188
4,882
6,868
0.5%
37Other non-current liabilities
1,031
815.6
1,751
3,026
4,160
2,362
2,015
1,279
1,423
922.8
965.7
(0.7)%
38Total Non-Current Liabilities
7,552
7,328
7,686
8,962
9,031
10,191
8,619
7,893
8,611
5,805
7,833
0.4%
39Total Liabilities
10,130
10,748
11,055
12,257
13,895
13,933
12,918
11,166
12,045
11,333
11,183
1%
SHAREHOLDERS` EQUITY
40Common stock
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
-
41Retained earnings / (deficit)
12,208
15,072
15,810
16,257
16,455
13,976
13,912
16,467
17,628
19,260
20,553
5.4%
42Accumulated other comprehensive income / (loss)
(224)
(319.9)
(318.4)
(240.4)
(135.2)
(299)
(106.7)
(164.9)
(153.7)
(136.2)
(182)
(2.1)%
43Noncontrolling interests
2.1
(11.5)
(14.7)
(8)
(4.1)
(14.2)
63.5
(9.5)
-
-
-
-
44Total shareholders' equity
9,375
12,129
12,598
13,032
13,335
10,686
10,960
13,388
14,799
16,716
18,257
6.9%
45Total Liabilities and shareholders' Equity
19,505
22,877
23,653
25,289
27,234
24,619
23,877
24,554
26,845
28,049
29,440
4.2%
46Total Debt
6,526
6,517
5,938
5,937
6,368
7,828
7,604
6,614
7,338
6,630
6,948
0.6%
47Net Debt
5,218
4,191
4,364
4,712
3,454
6,497
5,342
3,195
6,288
4,255
3,940
(2.8)%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
3,547
3,703
2,539
4,431
5,889
4,001
1,556
3,047
1,161
1,632
1,293
(9.6)%
49Depreciation & amortization
600.4
682.7
1,081
650.5
464.6
457.2
487.7
518.4
494.8
673.2
779.9
2.7%
50Share-based compensation expense
161.4
154.8
128
157.5
182.3
198.3
238.6
254.1
264.2
291.2
290.8
6.1%
51Changes in working capital and other assets
(592.7)
(17.9)
802.9
949
543.2
(426.3)
1,358
(2,435)
(372.9)
278.9
(159.5)
(12.3)%
52Net cash flows from operating activities
3,716
4,522
4,551
6,188
7,079
4,230
3,640
1,384
1,547
2,876
2,205
(5.1)%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(643)
(727.7)
(1,963)
(886.1)
(669.5)
(551.8)
(294.9)
(243.2)
(311.4)
(359.8)
(153.8)
(13.3)%
54Purchases of investments / marketable securities
(6,865)
(7,913)
(5,355)
(8,158)
(5,253)
(7,404)
(3,809)
(3,449)
(5,141)
-
(1,258)
(15.6)%
55Proceeds from maturities of marketable securities
4,063
7,379
5,566
9,174
6,486
7,374
3,499
4,661
8,289
551.5
79.7
(32.5)%
56Other investing activities
(1,109)
(1,223)
(1,211)
(2,176)
(93.7)
(26.9)
41
619.4
(6,925)
(990.9)
(38.7)
(28.5)%
57Net cash flows from investing activities
(4,554)
(2,485)
(2,963)
(2,046)
470.5
(608.6)
(563.7)
1,589
(4,089)
(799.2)
(1,371)
(11.3)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(4,946)
(956.3)
(1,371)
(4,355)
(5,868)
(6,684)
(1,801)
(751.9)
(44.3)
(31.3)
(10)
(46.2)%
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
5,928
(2.7)
(560.9)
(3.2)
-
1,467
(170)
(1,002)
187.3
(650)
(16.9)
-
61Other financing activities
3.8
(28.8)
(448.4)
(114.1)
7.9
(56.4)
(115.5)
(5.6)
(6)
(2.2)
(275)
-
62Net cash flows from financing activities
986.4
(987.8)
(2,380)
(4,472)
(5,860)
(5,273)
(2,086)
(1,760)
137
(683.5)
(301.9)
-
63Increase (decrease) in cash and cash equivalents
103.1
1,019
(752.7)
(349.2)
1,689
(1,583)
930.2
1,158
(2,369)
1,325
633.5
19.9%
64Cash and equivalents, ending balance
1,308
2,327
1,574
1,225
2,914
1,331
2,261
3,419
1,050
2,375
3,009
8.7%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
3,073
3,795
2,588
5,302
6,409
3,678
3,345
1,141
1,236
2,516
2,051
(4)%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Biogen (BIIB) financial statements and performance

Explore Biogen (BIIB) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.